BRAF/MEK Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events and Potential Drug Interactions.
نویسندگان
چکیده
BACKGROUND BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma. However, these regimens are associated with adverse events (AEs) that may lead to unnecessary drug modifications and discontinuations or potentially serious sequelae. In addition, drug-drug interactions (DDIs) may result in AEs or altered therapeutic efficacy. . OBJECTIVES This article presents consensus statements to guide nurses in the prevention, recognition, and management of AEs and potential DDIs associated with BRAF/MEK inhibitor therapy. . METHODS Members of the Melanoma Nurse Initiative reviewed the current literature and clinical experience related to AEs and DDIs associated with BRAF/MEK inhibitor therapy. . FINDINGS The care step pathways provided for select AEs represent a proactive, comprehensive nursing care plan to support optimal patient outcomes. Recommendations are also offered for preventing and managing DDIs.
منابع مشابه
PD-1 Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events .
BACKGROUND Programmed cell death protein 1 (PD-1) inhibitor therapies are now a standard treatment for advanced melanoma and other tumor types. The immune-related adverse events (irAEs) associated with PD-1 inhibitor therapy are drastically different from the AEs associated with chemotherapy. Because these irAEs reflect immune system activation rather than side effects of therapy, nurses should...
متن کاملPromoting Oral Therapy Adherence: Consensus Statements From the Faculty of the Melanoma Nursing Initiative on Oral Melanoma Therapies .
BACKGROUND Inhibitors of BRAF and the downstream signaling protein MEK have improved outcomes for patients with BRAF-mutant advanced malignant melanoma. Despite their ease of administration, these oral therapies pose adherence challenges. . OBJECTIVES This article aims to increase awareness of causes of nonadherence to oral targeted therapies in advanced malignant melanoma and to provide onc...
متن کاملDevelopment of encorafenib for BRAF-mutated advanced melanoma
PURPOSE OF REVIEW To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melanoma. RECENT FINDINGS Encorafenib has shown improved efficacy in the treatment of metastatic mela...
متن کاملNew developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-mutant melanoma. The progression-free survival after treatment with a BRAF inhibitor is modest, however, and BRAF inhibitors induce cutaneous toxicity, likely due to paradoxical activation of the mitogen-activated protein kinase pathway. Combining selective BRAF and MEK inhibition, such as the BRAF inhib...
متن کاملPanniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect
The combination of MEK inhibitor (cobimetinib, trametinib) and BRAF inhibitor (vemurafenib, dabrafenib) is now the first-line treatment in patients with BRAF V600-mutated metastatic melanoma. This association reduces cutaneous adverse events induced by BRAF inhibitors alone, including photosensitivity, hand-foot syndrome, hyperkeratosis, alopecia, skin papillomas, keratoacanthomas, and squamous...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical journal of oncology nursing
دوره 21 4 Suppl شماره
صفحات -
تاریخ انتشار 2017